ClinicalTrials.gg
CompletedNCT01985126Updated Jun 25, 2018Results posted

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

A Phase 2 interventional study of Daratumumab 16 mg/kg (Part 1) and Daratumumab 8 mg/kg (Part 1) in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
34th of 132
124 · median 50
Started
2013
the only one that year
Phase 2
73 of 132
7 open now
Registered
2nd of 132
by date
Lead sponsor
17 of 132
Janssen Research & Development, LLC

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 34th largest by enrollment, is the only one that started in 2013, is one of 73 in phase 2, and was the 2nd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are double refractory to a PI and an IMiD.

Read the detailed description

This is an open-label (identity of assigned study drug will be known) study of daratumumab for the treatment of participants with multiple myeloma who have received at least 3 prior lines of therapy including a PI and an IMiD or whose disease is double refractory to both a PI and an IMiD. Up to approximately 150 participants are to be enrolled. The study includes screening, treatment, and follow-up phases. Participants will receive daratumumab by intravenous infusion (28-day cycles) until disease progression, unacceptable toxicity, or other protocol-defined reasons. For all study drug administrations, participants will receive pre- and post-infusion medications for the prevention of infusion related reactions. Follow-up will continue until death, loss to follow up, consent withdrawal for study participation, or study end, whichever occurs first. The study will consist of 2 sequential parts (Part 1 and Part 2). The purpose of Part 1 is to select a dose and schedule for Part 2 of the study. Assessment of tumor response and disease progression will be conducted according to IMWG response criteria. Serial pharmacokinetic blood samples and a pharmacogenomic blood sample will be collected. Safety will be monitored throughout the study. At the end of the study, participants who are benefiting from treatment with daratumumab will have the option to continue treatment.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Daratumumab
  • Proteasome inhibitor
  • Immunomodulatory drug
  • IMiD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented multiple myeloma according to protocol-defined criteria
  • Evidence of disease progression on the most recent prior treatment regimen based on International Myeloma Working Group criteria
  • performance status score of 0, 1, or 2
  • Laboratory values and within protocol-defined parameters at screening

Exclusion criteria

Exclusion Criteria:

  • Received daratumumab or other anti-CD38 therapies previously
  • Nonsecretory multiple myeloma
  • Previously received an allogenic stem cell transplant or has received an stem cell transplantation within 12 weeks
  • Exhibiting clinical signs of meningeal involvement of multiple myeloma
  • Known , persistent asthma, or a history of asthma within 5 years
  • Seropositive for , or antibodies to hepatitis B surface and core antigens, or
  • Has plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Part 1

    During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.

    Drug: Daratumumab 16 mg/kg (Part 1) · Drug: Daratumumab 8 mg/kg (Part 1) · Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine

  • Experimental
    Part 2

    Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.

    Drug: Methylprednisolone · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Daratumumab (Part 2)

Interventions

  • DrugDaratumumab 16 mg/kg (Part 1)

    Drug page: Daratumumab

    Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion

  • DrugDaratumumab 8 mg/kg (Part 1)

    Drug page: Daratumumab

    Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion

  • Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted

  • 650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.

  • 25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.

  • Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response

    Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.

    Time frame: Up to 14.4 Months

Secondary outcomes

  1. Duration of Response

    Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in IMWG criteria. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component (the absolute increase must be \>=0.5 g/dL) and/or; urine M-component (the absolute increase must be \>=200 mg/24 hours) and/or; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 milligram per deciliter (mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter \[mmol/L\]) that can be attributed solely to the plasma cell proliferative disorder.

    Time frame: Up to 14.4 Months

  2. Overall Survival

    Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.

    Time frame: Approximately up to 3 years

  3. Percentage of Participants With Clinical Benefit

    Clinical benefit rate defined as percentage of participants who achieved minimal response (MR) or better. MR: \>=25% but \<= 49% reduction of serum M-protein and reduction in urine M-protein by 50%-89%. If present at baseline 25% to 49% reduction in size of soft tissue plasmacytomas.

    Time frame: Up to 14.4 Months

  4. Time to Response

    Time to response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better).

    Time frame: Up to 14.4 Months

  5. Progression Free Survival

    Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.

    Time frame: Up to 14.4 Months

  6. Time to Disease Progression

    Time to progression was defined as the number of days from the date of first dose of daratumumab to the date of first record of disease progression.

    Time frame: Up to 14.4 Months

07

Results

Posted Feb 2, 2017

Participant flow

Participant flow — Overall Study
MilestoneDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Started18106
Completed00
Not completed18106
Withdrew: Death1569
Withdrew: Lost to follow-up08
Withdrew: Study terminated by sponsor122
Withdrew: Withdrawal by subject27

Outcome measures

PrimaryPercentage of Participants With Overall Response

Overall response defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Per IMWG criteria, sCR: is defined as normal free light chain (FLC) ratio, and absence of clonal plasma cells (PCs) by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5 % plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or \>= 90% reduction in serum M-protein plus urine M-protein level \< 100mg/24 hours; PR: \>= 50 % reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>= 90% or to \<200 mg/24 hours; if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.

Time frame:
Up to 14.4 Months
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response
percentage of participantsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Percentage of Participants With Overall Response11.1 (1.4 to 34.7)29.2 (20.8 to 38.9)
SecondaryDuration of Response

Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in IMWG criteria. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component (the absolute increase must be \>=0.5 g/dL) and/or; urine M-component (the absolute increase must be \>=200 mg/24 hours) and/or; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \>10 milligram per deciliter (mg/dL); Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter \[mmol/L\]) that can be attributed solely to the plasma cell proliferative disorder.

Time frame:
Up to 14.4 Months
Reported as:
Median · months
Duration of Response
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Duration of ResponseNA (1.8 to NA)7.4 (5.5 to NA)
SecondaryOverall Survival

Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.

Time frame:
Approximately up to 3 years
Reported as:
Median · months
Overall Survival
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Overall Survival19.45 (7.72 to 26.81)18.60 (13.67 to 25.00)
SecondaryPercentage of Participants With Clinical Benefit

Clinical benefit rate defined as percentage of participants who achieved minimal response (MR) or better. MR: \>=25% but \<= 49% reduction of serum M-protein and reduction in urine M-protein by 50%-89%. If present at baseline 25% to 49% reduction in size of soft tissue plasmacytomas.

Time frame:
Up to 14.4 Months
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit
percentage of participantsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Percentage of Participants With Clinical Benefit22.2 (6.4 to 47.6)34.0 (25.0 to 43.8)
SecondaryTime to Response

Time to response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better).

Time frame:
Up to 14.4 Months
Reported as:
Median · months
Time to Response
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Time to Response0.99 (0.95 to 1.02)0.99 (0.9 to 5.6)
SecondaryProgression Free Survival

Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first.

Time frame:
Up to 14.4 Months
Reported as:
Median · months
Progression Free Survival
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Progression Free Survival4.86 (1.84 to NA)3.65 (2.76 to 4.63)
SecondaryTime to Disease Progression

Time to progression was defined as the number of days from the date of first dose of daratumumab to the date of first record of disease progression.

Time frame:
Up to 14.4 Months
Reported as:
Median · months
Time to Disease Progression
monthsDaratumumab 8 mg/kgDaratumumab 16 mg/kg
Time to Disease Progression4.86 (1.84 to NA)3.71 (2.79 to 5.39)

Adverse events

Collected over Approximately up to 3.8 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daratumumab 8 mg/kg—6/18 (33.3%)18/18 (100%)
Daratumumab 16 mg/kg—33/106 (31.1%)105/106 (99.1%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventDaratumumab 8 mg/kgDaratumumab 16 mg/kg
NauseaGastrointestinal disorders1/180/106
VomitingGastrointestinal disorders1/180/106
General Physical Health DeteriorationGeneral disorders1/185/106
HyperuricaemiaMetabolism and nutrition disorders1/180/106
Back PainMusculoskeletal and connective tissue disorders1/181/106
Plasma Cell LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/180/106
SyncopeNervous system disorders1/180/106
Acute Kidney InjuryRenal and urinary disorders1/180/106
Renal ImpairmentRenal and urinary disorders1/180/106
Urinary RetentionRenal and urinary disorders1/180/106
Most frequent other events
Showing 10 of 110
Most frequent other events
EventDaratumumab 8 mg/kgDaratumumab 16 mg/kg
AnaemiaBlood and lymphatic system disorders9/1839/106
HypertensionVascular disorders8/1812/106
FatigueGeneral disorders6/1842/106
Blood Creatinine IncreasedInvestigations7/189/106
ThrombocytopeniaBlood and lymphatic system disorders6/1828/106
ChillsGeneral disorders6/1810/106
HyponatraemiaMetabolism and nutrition disorders6/187/106
CoughRespiratory, thoracic and mediastinal disorders6/1827/106
NauseaGastrointestinal disorders4/1834/106
PyrexiaGeneral disorders5/1820/106

Baseline characteristics

All treated Analysis Set included all participants who received at least 1 dose of daratumumab.

Age, Categorical
Age, Categorical(Participants)Daratumumab 8 mg/kgDaratumumab 16 mg/kgTotal
<=18 years000
Between 18 and 65 years85866
>=65 years104858
Age, Continuous
Age, Continuous(years)Daratumumab 8 mg/kgDaratumumab 16 mg/kgTotal
Mean64.2 ± 7.7262.9 ± 1063.1 ± 9.68
Sex: Female, Male
Sex: Female, Male(Participants)Daratumumab 8 mg/kgDaratumumab 16 mg/kgTotal
Female65460
Male125264
Region of Enrollment
Region of Enrollment(Participants)Daratumumab 8 mg/kgDaratumumab 16 mg/kgTotal
Canada02222
Spain3912
United States157590
Stage of Disease (ISS)
Stage of Disease (ISS)(Participants)Daratumumab 8 mg/kgDaratumumab 16 mg/kgTotal
I22628
II84048
III84048
Number of Prior Lines of Therapy
Number of Prior Lines of Therapy(Participants)Daratumumab 8 mg/kgDaratumumab 16 mg/kgTotal
<= 3 Lines61925
> 3 Lines128799
Refractory to Proteasome Inhibitor (PI)/ Immunomodulatory Drug (IMiD)
Refractory to Proteasome Inhibitor (PI)/ Immunomodulatory Drug (IMiD)(Participants)Daratumumab 8 mg/kgDaratumumab 16 mg/kgTotal
Both a PI and IMiD15101116
PI only134
IMiD only011
None213
08

Study locations

23 sites
  • Duarte, California, United States
  • Los Angeles, California, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Louisville, Kentucky, United States
  • Detroit, Michigan, United States
  • New Brunswick, New Jersey, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • Madison, Wisconsin, United States
  • Calgary, Alberta, Canada
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Halifax, Nova Scotia, Canada
  • Montreal, Quebec, Canada
  • Barcelona, Spain
  • Salamanca N/A, Spain
  • Valencia, Spain
09

References and documents

Publications

  • Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447-e455. doi: 10.1016/S2352-3026(20)30081-8. PubMed 32470437 ↗
  • Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11. PubMed 30536810 ↗
  • Usmani SZ, Khan I, Chiu C, Foureau D, Druhan LJ, Rigby K, Casneuf T, Sasser AK. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma. Exp Hematol Oncol. 2018 Feb 7;7:3. doi: 10.1186/s40164-018-0096-7. eCollection 2018. PubMed 29445583 ↗
  • Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15. PubMed 27307294 ↗
  • Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7. PubMed 26778538 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Jan 2015, 15 months.

Results were first posted in Feb 2017, 2 years after primary completion.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 15 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2013
First posted
Nov 15, 2013
StartActual
Sep 27, 2013
Primary completionActual
Jan 9, 2015
CompletionActual
May 30, 2017
Results first posted
Feb 2, 2017
Last update
Jun 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01985126
Responsible party
Sponsor
First posted
Nov 15, 2013
Start date
Sep 27, 2013
Primary completion
Jan 9, 2015
Completion
May 30, 2017
Results posted
Feb 2, 2017
Last update
Jun 25, 2018

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion